Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Andy Trotti MD
Closed to Accrual
Head and Neck [HN]
Head and Neck
To determine whether substitution of cisplatin with cetuximab will result in comparable 5-year overall survival
Closed to both Step 1 and Step 2 Registration.
Note: If your site is in possession of an RTOG 1016 study iPad, contact Robert Pickard at email@example.com or 1-614-292-0875 to make arrangements for the return of the iPad.
The quality of life (QOL) component met its accrual objective (400 patients) and closed to accrual on 2/28/13.
Squamous cell carcinoma of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls); stage T1-2, N2a-3, or T3-4 any N; patient tumor must be p16 positive
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.